Impact of Low-Dose Dronabinol Therapy on Cognitive Function in Cancer Patients Receiving Palliative Care: A Case-Series Intervention Study.
| Autor: | Buchwald D; Centre for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark.; Department of Communication and Psychology, Aalborg University, Aalborg, Denmark., Schmidt C; Department of Communication and Psychology, Aalborg University, Aalborg, Denmark., Buchwald D; Centre for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark.; Palliative Care Team, Department of Gerontology, North Denmark Regional Hospital, Hjørring, Denmark., Winter KI; Centre for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark.; Palliative Care Team, Department of Gerontology, North Denmark Regional Hospital, Hjørring, Denmark., Nielsen IB; Palliative Care Team, Department of Gerontology, North Denmark Regional Hospital, Hjørring, Denmark., Klostergaard K; Centre for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark., Melgaard D; Centre for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark.; Department of Communication and Psychology, Aalborg University, Aalborg, Denmark., Fagerberg SK; Centre for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark., Leutscher PDC; Centre for Clinical Research, North Denmark Regional Hospital, Hjørring, Denmark.; Palliative Care Team, Department of Gerontology, North Denmark Regional Hospital, Hjørring, Denmark. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Palliative medicine reports [Palliat Med Rep] 2023 Dec 07; Vol. 4 (1), pp. 326-333. Date of Electronic Publication: 2023 Dec 07 (Print Publication: 2023). |
| DOI: | 10.1089/pmr.2023.0024 |
| Abstrakt: | Background: Cannabis may offer therapeutic benefits to patients with advanced cancer not responding adequately to conventional palliative treatment. However, tolerability is a major concern. Cognitive function is a potential adverse reaction to tetrahydrocannabinol containing regimens. The aim of this study was to test cognitive function in patients being prescribed dronabinol as an adjuvant palliative therapy. Methods: Adult patients with advanced cancer and severe related pain refractory to conventional palliative treatment were included in this case-series study. Patients were examined at baseline in conjunction with initiation of dronabinol therapy and at a two-week follow-up using three selected Wechsler's adult intelligence scale III neurocognitive tests: Processing Speed Index (PSI), Perceptual Organization Index (POI), and Working Memory Index (WMI). Patients were also assessed using pain visual analog scale, Major Depression Inventory, and Brief Fatigue Inventory. Results: Eight patients consented to take part in the study. Two patients discontinued dronabinol therapy, one due to a complaint of dizziness and another critical progression of cancer disease, respectively. The remaining six patients were successfully treated with a daily dosage of 12.5 mg dronabinol ( p = 0.039). PSI ( p = 0.020), POI ( p = 0.034.), and WMI ( p = 0.039). Conclusions: Cognitive function improved in this group of patients with advanced cancer in conjunction with low-dose dronabinol therapy. The cause is likely multifactorial including reported relief of cancer-associated symptoms. Further clinical investigation is required. Competing Interests: The authors do not have potential conflicts of interest, including relevant financial interests, activities, relationships, and affiliations related to this article. (© Ditte Buchwald et al., 2023; Published by Mary Ann Liebert, Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|